These data suggest that the vaccine with the active component being recombinant proteins 4 and 5, as well as other proteins based on conserved fragments of IgA1 protease, will protect people from infection not only with meningococci, but also with other pathogens that produce serine IgA1 proteases with similar amino acid sequences. The gene discussed is IGHA1; the disease is infection.